MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1101/2024.09.03.24313019

Медицинская библиотека · medRxiv : the preprint server for health sciences · 2024

Neurodegenerative Plasma Biomarkers for Prediction of Hippocampal Atrophy in Older Adults with Suspected Alzheimer's Disease in Kinshasa, Democratic Republic of Congo.

Ikanga Jean, Jean Kharine, Medina Priscilla, Patel Saranya Sundaram, Schwinne Megan, Epenge Emmanuel, Gikelekele Guy, Tshengele Nathan, Kavugho Immaculee, Mampunza Samuel, Mananga Lelo, Teunissen Charlotte E, Stringer Anthony, Rojas Julio C, Chan Brandon, Lago Argentina Lario, Kramer Joel H, Boxer Adam L, Jeromin Andreas, Hanseeuw Bernard, Gross Alden L, Alonso Alvaro

СтатьяПрепринтПеревод пока не подготовлен

Аннотация

OBJECTIVE

The hippocampus is one of the first brain structures affected by Alzheimer's disease (AD), and its atrophy is a strong indicator of the disease. This study investigates the ability of plasma biomarkers of AD and AD-related dementias-amyloid-β (Aβ42/40), phosphorylated tau-181 (p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP)-to predict hippocampal atrophy in adult individuals in Kinshasa, Democratic Republic of Congo (DRC).

METHODS

Eighty-five adult individuals (40 healthy and 45 suspected AD) over 65 years old were evaluated using the Community Screening Instrument for Dementia and Alzheimer's Questionnaire (AQ). Core AD biomarkers (Aβ42/40 and p-tau181) and non-specific neurodegeneration biomarkers (NfL, GFAP) were measured in blood samples collected at the study visit. Hippocampal volumes were measured using magnetic resonance imaging (MRI). General linear regression was used to evaluate differences in biomarker concentrations by neurological status. Logistic regression models were used to create receiver operating characteristic curves and calculate areas under the curve (AUCs) with and without clinical covariates to determine the ability of biomarker concentrations to predict hippocampal atrophy. Plasma biomarkers were used either individually or in combination in the models.

RESULTS

Elevated p-tau181 was associated with left hippocampal (LH) atrophy p= 0.020). Only higher p-tau181 concentrations were significantly associated with 4.2-fold increased odds [OR=4.2 (1.5-18.4)] of hippocampal atrophy per standard deviation. The AUC of plasma biomarkers without clinical covariates to discriminate LH, RH, and total hippocampal (TH) or both hippocampi atrophy ranged between 90% to 94%, 76% to 82%, and 85% to 87%, respectively. The AUC of models including clinical covariates and AD biomarkers used in combination to discriminate LH, RH, and TH ranged between 94%-96%, 81%-84%, and 88%-90%, respectively.

CONCLUSION

These results indicate that, consistent with studies in other settings, core AD plasma biomarkers can predict hippocampal atrophy in a population in Sub-Saharan Africa.

Для цитирования: Ikanga Jean, Jean Kharine, Medina Priscilla, Patel Saranya Sundaram, Schwinne Megan, Epenge Emmanuel, Gikelekele Guy, Tshengele Nathan, Kavugho Immaculee, Mampunza Samuel, Mananga Lelo, Teunissen Charlotte E, Stringer Anthony, Rojas Julio C, Chan Brandon, Lago Argentina Lario, Kramer Joel H, Boxer Adam L, Jeromin Andreas, Hanseeuw Bernard, Gross Alden L, Alonso Alvaro. Neurodegenerative Plasma Biomarkers for Prediction of Hippocampal Atrophy in Older Adults with Suspected Alzheimer's Disease in Kinshasa, Democratic Republic of Congo.. medRxiv : the preprint server for health sciences. 2024. DOI: 10.1101/2024.09.03.24313019.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.